





































The Effect of Pulse Width on Subjective Memory Impairment
and Remission Rate 6 Months After Electroconvulsive Therapy
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Objectives: The aim of this study was to compare the 0.5-millisecond
pulse width with broader brief width stimulus and ultrabrief pulse width
stimulus in respect to rates of subjective memory impairment and
remission 6 months after completion of electroconvulsive therapy (ECT).
Methods: This study used data from the Swedish National Quality Reg-
ister for ECT. Inclusion criteria were bipolar or unipolar depression with or
without psychosis, ECTwith unilateral electrode placement, and data on
the Montgomery-Åsberg Depression Rating Scale—Self-Assessment and
the memory item of the Comprehensive Psychopathological Rating Scale
(CPRS-M) before and 6 months after ECT. The primary outcomes were
the distributions of patients with a maximum of 10 on the Montgomery-
Åsberg Depression Rating Scale—Self-Assessment (remission) and a min-
imum of 2-step worsening in CPRS-M score according to the ECT pulse
widths of <0.5, 0.5, and >0.5 millisecond.
Result: This study included 312 patients. The distributions of patients
with remission or a minimum of 2-step worsening on the CPRS-M
6 months after completion of ECT showed no significant differences be-
tween the 3 pulse width groups. Older age was associated with a signifi-
cantly higher rate of remission 6 months after ECT.
Conclusions: In this cohort of patients, no support was found for the pre-
vious research finding of lower rates of subjective memory disturbances
6 months after ultrabrief pulse width ECT in comparison with brief pulse
width ECT. Older age was associated with higher remission rate 6 months
after ECT. Large randomized studies are required to exclude the possibility
of long-term differential effects between pulse widths.
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A lthough electroconvulsive therapy (ECT) is an effective treat-ment of severe depression,1 memory impairment is a com-
mon side effect. A number of strategies have been tried to
minimize this impairment, including unilateral electrode place-
ment rather than bilateral, and shorter pulse widths. However,
there is a trade-off between maximal efficacy and minimal
memory impairment.1,2
Pulse width techniques can be classified as ultrabrief
pulse (UBP; 0.3–<0.5 millisecond) and brief pulse (BP; 0.5–
1 millisecond).3 The Sackeim group showed that the cognitive
outcomes of the unilateral UBP technique were superior to
those of bilateral and BP techniques, whereas the efficacy
seemed to be similar to that of the unilateral BP technique.4
A recent meta-analysis confirmed the superiority of UBP to
BP in regard to cognitive outcomes within the first week of
ECT, but showed the disadvantage of a lower remission rate.5
In addition, UBP requires more sessions than BP to achieve a
similar treatment effect.6
In a randomized trial, UBP showed a favorable difference in
long-term memory effects 6 months after treatment in comparison
with BP.4 If these results are confirmed, they would provide evi-
dence for long-term ECT-induced memory deficits that would
need to be considered when prescribing ECT. Moreover, they
could mean that UBP should be considered as the first-line ECT
technique, with the BP technique being reserved for cases that
do not respond adequately to the UBP technique. Currently,
unilateral electrode placement with a pulse width of 0.5 milli-
second is primarily used in Sweden, but there is variation
across hospitals regarding the pulse widths used. Therefore, it
is possible to analyze the impact of pulse width on the out-
comes of ECT.7
The aim of this study was to compare the current
Swedish standard 0.5-millisecond pulse width with broader
BP-width and UBP-width stimuli in respect to rates of sub-




This study is a register-based analysis using information
from the Swedish National Quality Register for ECT (Q-ECT).
For the years 2012 onward, the Q-ECT contains ECT-related data
from all hospitals in Sweden offering ECT.8 Data from the period
January 2017 to June 2018 were retrieved for this study.
Participants
The study population consisted of patients with bipolar and
unipolar depression with or without psychosis. The depressive epi-
sode could be severe to moderate. The International Statistical
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Classification of Disease and RelatedHealth Problems, Tenth Revi-
sion codes of F33.3, F32.3, F31.5, F33.2, F31.4, F32.2, F33.1,
F32.1, and F31.3 were included.9 The diagnosis providing the indi-
cation for ECTwas confirmed by the referring psychiatrist. An ad-
ditional inclusion criterion was initial right unilateral electrode
placement. Patients treated with ECT were asked to fill out a
follow-up inquiry approximately 6 months after ECT. This follow-up
inquiry included the memory item of the Comprehensive Psycho-
pathological Rating Scale (CPRS-M)10 and the Montgomery Åsberg
Depression Rating Scale—self-rated version (MADRS-S).11 These
scales are also routinely used in the register within a week before
ECT. Patients who completed the 6-month follow-up inquiry within
4 to 10 months after ECTwere included in this study. The patient
data required for inclusion in this study were the MADRS-S and
CPRS-M score, both before and 6 months after ECT.
ECT Technique
The study population were treated with either Mecta (Mecta
Corp, Lake Oswego, Ore) or Thymatron ECT devices (Somatics,
Inc., Lake Bluff, Ill). Unilateral electrode placement according to
d'Eliawas used. Of the total of 312 patients, 46 were treated with a
pulse width <0.5 millisecond, 187 with a pulse width of 0.5 milli-
second, and 79 with a pulse width >0.5 millisecond. The mean
(SD) electrical dosages used in the different pulse width groups
were 243.7 (108.2) mC for <0.5 millisecond, 333.9 (119.2) mC
for 0.5 millisecond, and 466.2 (150.8) mC for >0.5 millisecond.
The mean (SD) numbers of sessions in the different pulse width
groups were 8.1 (3.1), 8.1 (3.5), and 8.2 (3.4) for <0.5, 0.5, and
>0.5 millisecond, respectively. The standard frequency of sessions
in Sweden is 3 times per week. The anesthetics used were
propofol, thiopental, remifentanil, or ketamine; the full details of
these are given in Table 1. Further details on the ECT techniques
including frequency, duration, current, charge, and seizure duration
are described in Supplementary Table 1 (Supplemental Digital
Content 1, http://links.lww.com/JECT/A103).
Variables
Patients rated their subjective memory impairment in the
follow-up inquiry 6 months after completion of ECT, with the
question being adapted from the memory question in the CPRS.
The questionnaire was sent out to the patients and returned to
the hospital by post; this routine is recommended by the register
from 2016 onward. The scale for memory impairment was as fol-
lows: 0, no experience of memory impairment; 2, experience of
temporarymemory impairment; 4, experience of socially inconve-
nient or distressing memory impairment; and 6, experience of
complete inability to remember. In a study on subjective memory
impairment following ECT, this scale has been compared with the
Global Self-Evaluation of Memory and Mood.12,13
The pulse width at which ECT was initiated was retrieved
from the Q-ECT. Patients were categorized into 3 groups accord-
ing to the pulse width at which treatment was initiated: <0.5, 0.5,
or >0.5 millisecond. The 3 pulse width groups were chosen in this
study because 0.5 millisecond is the most commonly used in
Sweden but less studied than the 0.3- and 1.0-millisecond pulse
widths. The diagnoses were categorized into four groups: unipolar
depression with psychosis, unipolar depression without psycho-
sis, bipolar depression with psychosis, and bipolar depression
without psychosis. The MADRS-S scores before ECTwere cate-
gorized into 3 groups: 1–19, 20–34, and≥35, as were the numbers
of sessions: 1–5, 6–9, and ≥10. The anesthetics used during the
ECT were categorized into 3 groups: propofol, thiopental, and
other. The “other” group included ketamine or a combination
of anesthetics including propofol, thiopental, ketamine, and
remifentanil. Other medications taken during the period of
ECTwere categorized into 5 groups: benzodiazepines, lithium,
antipsychotics, antidepressants, and antiepileptics. If no medi-
cation was noted in the register, it was interpreted to mean that
no medication was prescribed during ECT. Follow-up times
were categorized into <5, 5–7, and >7 months.
Outcomes
TheMADRS-S scores after 6 monthswere categorized into 2
groups: 0–10 and >10. Patients with aMADRS-S score between 0
and 10 after 6 months were viewed as being in remission, whereas
those with a MADRS-S score >10 were viewed as nonremission.
Electroconvulsive therapy–induced subjective memory impair-
ment was defined as a minimum 2-step worsening in the CPRS
score from before ECT to 6 months after ECT. Examples of a
2-step worsening are change from 0 to 2 or 3 to 5. The primary
outcomeswere the distributions of remission and subjective mem-
ory impairment according to the 3 different pulse width groups.
Statistical Methods
The data collected from the Q-ECT were processed using
SAS 9.4 (SAS Institute, Cary, North Carolina) and SPSS 25
(IBM Corp, Armonk, New York). Differences in the distributions
of patient characteristics between the different pulse width groups
were calculated using χ2 tests. The associations between a
minimum 2-step worsening in the CPRS-M score and the
potential cofounding variables of sex, age group, number of
sessions, anesthetics, medications during the period of ECT,
MADRS-S 6 months after completion of ECT, and pulse width
were evaluated in 2 multivariate analyses performed using
logistic regression with and without follow-up time. Logistic
regression was also used to evaluate the association between
nonremission and the potential cofounding variables of sex, age
group, number of sessions, anesthetics, other medications
during the period of ECT, and pulse width group, with and
without follow-up time. Statistical significance was defined
as P < 0.05.
Ethics
This study is part of the research project “Outcome of Treat-
ment for Severe Affective Disorders,” which was approved by the
regional ethical vetting board in Uppsala, Sweden (registration no.
2014/174/3). Before a patient's information was entered into the
Q-ECT, the patient was informed of the register and the future
use of the data for research, and had the option to decline partici-
pation. No information about this specific study was given to
the participants.
RESULTS
A total of 312 patients were identified, 58% female and 42%
male. Of these, 84%were diagnosed with unipolar depression and
16% were diagnosed with bipolar depression. Seventeen percent
of the patients had psychotic features before ECT. Of the
312 patients, 71 were treated as outpatients, and 240 were treated
as inpatients; the data for one patient was missing. The study pop-
ulation and the different variables were similarly distributed among
the different pulse width groups, as they were in the patients in the
Q-ECT from the same time period that were not included in this
study (reference population). The characteristics of the study popu-
lation and the reference population are described in Table 1.
The 2 patient characteristic variables of sex and age group
showed statistically significant differences in distribution among
the different pulse width groups. Men tended to be treated with
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longer pulse widths compared with women, and increasing age
correlated with the use of longer pulse widths. The distributions
of diagnosis, MADRS-S before ECT, and number of sessions
did not differ significantly between the different pulse width
groups (Table 1). Propofol was more often used in the >0.5-milli-
second pulse width group, and benzodiazepines and antiepileptics
were more prevalent in the <0.5-millisecond pulse width group.
The MADRS-S 6 months after ECT displayed a nonsignificant
tendency for more participants to be in remission with the longer
pulse widths (Table 1).
The CPRS-M scores before and 6 months after ECT showed
no significant differences in distribution between the different
TABLE 1. Patient Characteristics According to the Different Pulse Width Groups
<0.5 ms 0.5 ms >0.5 ms Total
P*
Reference†
n % n % n % n % n %
Sex 0.019
Female 33 71.7 112 59.9 37 46.8 182 58.3 2289 61.6
Male 13 28.3 75 40.1 42 53.2 130 41.7 1427 38.4
Age, y 0.000
16–39 23 50.0 50 26.7 13 16.5 86 27.6 885 23.8
40–64 13 28.3 85 45.5 32 40.5 130 41.7 1430 38.5
≥65 10 21.7 52 27.8 34 43.0 96 30.8 1400 37.7
Diagnosis 0.706
Unipolar depression with psychosis 7 15.2 27 14.4 15 19.0 49 15.7 651 17.5
Unipolar depression without psychosis 30 65.2 131 70.1 53 67.1 214 68.6 2350 63.2
Bipolar depression with psychosis 1 2.2 1 0.5 2 2.5 4 1.3 112 3.0
Bipolar depression without psychosis 8 17.4 28 15.0 9 11.4 45 14.4 603 16.2
MADRS-S before ECT 0.959
0–19 2 4.3 9 4.8 5 6.3 16 5.1 210 8.3
20–34 22 47.8 97 51.9 39 49.4 158 50.6 1150 45.3
≥35 22 47.8 81 43.3 35 44.3 138 44.2 1179 46.4
MADRS-S after 6 mo 0.052
0–10 12 26.1 78 41.7 38 48.1 128 41.0 119 44.9
>10 34 73.9 109 58.3 41 51.9 184 59.0 146 55.1
No. sessions 0.846
1–5 6 13.0 26 13.9 7 8.9 39 12.5 801 21.6
6–9 29 63.0 113 60.4 51 64.6 193 61.9 2092 56.3
≥10 11 23.9 48 25.7 21 26.6 80 25.6 823 22.1
Anesthetics 0.000
Propofol 23 50.0 85 45.5 58 73.4 166 53.2 1383 37.2
Thiopental 23 50.0 66 35.3 11 13.9 100 32.1 2014 54.2
Other‡ 0 0.0 36 19.3 10 12.7 46 14.7 319 8.6
Medication during ECT
Antidepressants
No 6 13.0 22 11.8 10 12.7 38 12.2 0.961 722 19.4
Yes 40 87.0 165 88.2 69 87.3 274 87.8 2994 80.6
Lithium
No 38 82.6 164 87.7 65 82.3 267 85.6 0.426 3059 82.3
Yes 8 17.4 23 12.3 14 17.7 45 14.4 657 17.7
Benzodiazepine
No 18 39.1 120 64.2 44 55.7 182 58.3 0.007 1961 52.8
Yes 28 60.9 67 35.8 35 44.3 130 41.7 1755 47.2
Antiepileptics
No 33 71.7 162 86.6 71 89.9 266 85.3 0.016 3106 83.6
Yes 13 28.3 25 13.4 8 10.1 46 14.7 610 16.4
Antipsychotics
No 33 71.7 119 63.6 53 67.1 205 65.7 0.558 1918 51.6
Yes 13 28.3 68 36.4 26 32.9 107 34.3 1798 48.4
*Between pulse width groups. Calculated using Pearson χ2 test.
†Data from the excluded patients from this study treated for depression in the Q-ECT from the same time period.
‡Other contains ketamine or a combination of the anesthetics including ketamine, remifentanil, propofol, and thiopental.
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pulse width groups. The median CPRS-M score in the total popu-
lation of participants and in all separate pulse width groups was 2,
both before and 6 months after ECT. The upper (Q1) and lower
(Q3) quartile pre-ECT CPRS-M values in the different pulse
width groups were 1 and 4, 1 and 4, and 0 and 3 for <0.5, 0.5,
and >0.5 millisecond, respectively, whereas they were 0.75 and
4, 1 and 4, and 0 and 3, respectively, at 6 months after ECT.
The effects of potential cofounding variables on a minimum
2-step worsening in CPRS-M score were evaluated in a multivar-
iate analysis using logistic regression. This analysis included the
variables of sex, age group, pulse width group, MADRS-S score
6 months after completion of ECT, number of sessions, anes-
thetics, and other medication during the period of ECT.
The results displayed no statistically significant associations
between subjective memory worsening 6 months after completion
of ECTand sex, age group, pulse width group, number of sessions,
anesthetics, or other medications during the period of ECT.
However, patients in remission had a significantly lower risk
of experiencing subjective memory worsening 6 months after
completion of ECT compared with patients not in remission
(P < 0.001; odds ratio [OR], 0.29; 95% confidence interval
[CI], 0.15–0.57; Table 2).
TABLE 2. The Impact of Potential Cofounding Variables on Subjective Memory worsening
Multivariate Analysis*
Worsening, n (%) No Worsening, n (%) OR (95% CI) P
Sex
Female 48 (26.4) 134 (73.6) 1.349 (0.742–2.451) 0.326
Male 27 (20.8) 103 (79.2) Reference category
Age, y
16–39 29 (33.7) 57 (66.3) 1.926 (0.868–4.275) 0.107
40–64 30 (23.1) 100 (76.9) 1.266 (0.603–2.655) 0.533
≥65 16 (16.7) 80 (83.3) Reference category
Pulse width
<0.5 ms 12 (26.1) 34 (73.9) 0.471 (0.180–1.237) 0.127
0.5 ms 41 (21.9) 146 (78.1) 0.575 (0.292–1.133) 0.110
>0.5 ms 22 (27.8) 57 (72.2) Reference category
MADRS-S after 6 mo
0–10 15 (11.7) 113 (88.3) 0.293 (0.151–0.568) 0.000
>10 60 (32.6) 124 (67.4) Reference category
No. sessions
1–5 9 (23.1) 30 (76.9) 1.114 (0.464–2.678) 0.809
6–9 45 (23.3) 148 (76.7 Reference category
≥10 21 (26.3) 59 (73.8) 0.930 (0.483–1.790) 0.828
Anesthetics
Propofol 45 (27.1) 121 (72.9) 2.063 (0.822–5.174) 0.123
Thiopental 22 (22.0) 78 (78.0) 1.778 (0.657–4.811) 0.257
Other† 8 (17.4) 38 (82.6) Reference category
Medication during ECT
Antidepressants
No 11 (28.9) 27 (71.1) Reference category 0.751
Yes 64 (23.4) 210 (76.6) 0.873 (0.377–2.020)
Lithium
No 63 (23.6) 204 (76.4) Reference category 0.621
Yes 12 (26.7) 33 (73.3) 0.819 (0.371–1.808)
Benzodiazepine
No 46 (25.3) 136 (74.7) Reference category 0.358
Yes 29 (22.3) 101 (77.7) 0.750 (0.406–1.386)
Antiepileptics
No 60 (22.6) 206 (77.4) Reference category 0.169
Yes 15 (32.6) 31 (67.4) 1.699 (0.798–3.619)
Antipsychotics
No 51 (24.9) 154 (75.1) Reference category 0.388
Yes 24 (22.4) 83 (77.6) 0.768 (0.423–1.397)
Worsening is defined as a minimum of 2-step worsening of the CPRS-M score.
*Calculated using logistic regression.
†Other contains ketamine or a combination of anesthetics including ketamine, remifentanil, propofol, and thiopental.
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The relationships between remission and the variables of sex,
age group, pulse width group, number of sessions, anesthetics,
and other medication during the period of ECT were evaluated
using multivariate logistic regression. The results showed no sta-
tistically significant associations between remission and sex, pulse
width, number of sessions, anesthetics, or other medication during
the period of ECT. However, the remission rate showed a statisti-
cally significant association with age group, with nonremission
6 months after completion of ECT being more likely in the age
group of 16 to 39 years and nearly significantly more likely for
the age group of 40–64 years (P < 0.001 [OR, 5.02; 95% CI,
2.46–10.28] and P = 0.061 [OR, 1.71; 95% CI, 0.98–3.02], re-
spectively) than in patients older than 65 years (Table 3). The pro-
portion of patients achieving remission in the youngest age group
was 18.6%, whereas 62.2% achieved remission in the oldest age
group (Fig. 1). In comparison with a follow-up time of >7 months
(reference), a follow-up time of <5 or 5–7 months did not
significantly affect nonremission (P = 0.228 [OR, 2.038; 95%
CI, 0.640–6.494] and P = 0.425 [OR, 1.256; 95% CI,
0.718–2.196], respectively) or memory worsening (P = 0.229
[OR, 0.426; 95% CI, 0.106–1.713] and P = 0.657 [OR, 0.355;
95% CI, 0.355–1.214]).
DISCUSSION
No statistically significant differences in the distribution of
subjective memory worsening or remission rate 6 months after
completion of ECTwere found between the different pulse width
groups, and this study therefore provides no support for the hy-
pothesis that BP ECT (>0.5 millisecond) results in higher rates
of 6-month subjective memory impairment and remission in com-
parison with UBP ECT.
The age group had a large effect on the remission rate
6 months post-ECT. Previous research has shown that older age
TABLE 3. Associations Between Nonremission and the Variables of Sex, Age Group, and Pulse Width
Remission, n (%) Not in Remission, n (%) Multivariate Analysis*
Sex
Female 68 (37.4) 114 (62.6) 1.356 (0.813–2.262) 0.243
Male 60 (46.2) 70 (53.8) Reference category
Age, y
16–39 16 (18.6) 70 (81.4) 5.024 (2.456–10.277) 0.000
40–64 56 (43.1) 74 (56.9) 1.711 (0.975–3.022) 0.061
≥65 56 (62.2) 40 (41.7) Reference category
Pulse width
<0.5 ms 12 (26.1) 34 (73.9) 1.749 (0.706–4.330) 0.227
0.5 ms 78 (41.7) 109 (58.3) 1.129 (0.624–2.045) 0.688
>0.5 ms 38 (48.1) 41 (51.9) Reference category
No. sessions
1–5 21 (53.8) 18 (46.2) 0.565 (0.267–1.194) 0.135
6–9 83 (43.0) 110 (57.0) Reference category
≥10 24 (30.0) 56 (70.0) 1.479 (0.806–2.714) 0.207
Anesthetics
Propofol 66 (39.8) 100 (60.2) 1.208 (0.575–2.536) 0.618
Thiopental 42 (42.0) 58 (58.0) 1.154 (0.522–2.549) 0.724
Other† 20 (43.5) 26 (56.5) Reference category
Medication during ECT
Antidepressants
No 14 (36.8) 24 (63.2) Reference category 0.485
Yes 114 (41.6) 160 (58.4) 0.758 (0.349–1.648)
Lithium
No 113 (42.3) 154 (57.7) Reference category 0.491
Yes 15 (33.3) 30 (66.7) 1.297 (0.619–2.718)
Benzodiazepine
No 75 (41.2) 107 (58.8) Reference category 0.818
Yes 53 (40.8) 77 (59.2) 1.066 (0.622–1.827)
Antiepileptics
No 112 (42.1) 154 (57.9) Reference category 0.974
Yes 16 (34.8) 30 (65.2) 1.012 (0.486–2.109)
Antipsychotics
No 88 (42.9) 117 (57.1) Reference category 0.417
Yes 40 (37.4) 67 (62.6) 1.241 (0.737–2.090)
Remission is defined as a MADRS-S score of 0–10 at six months after completion of ECT. Non-remission is defined as a MADRS-S score of >10.
*Calculated using logistic regression.
†Other contains ketamine or a combination of anesthetics including ketamine, remifentanil, propofol, and thiopental.
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is associated with higher remission rates immediately after ECT14
and lower relapse rates. Thus, this finding is in line with previous
research showing superior outcomes for ECT in patients of
older age.
A few studies have shown that BP ECT required a lower
number of sessions than UBP ECT,6,15 and that a high number
of sessions increases the risk of cognitive side effects.4 However,
no such patterns were found in this study.
Seventeen percent of the study population showed psychotic
features, and this relatively low proportion may have been influ-
enced by the inclusion criterion stating that patients needed to
have completed the MADRS-S and CPRS-M forms before ECT.
Severely catatonic or psychotic patients may have difficulty in
completing these forms. This may have limited the remission rate
in the study because patients with psychotic features tend to have
better outcomes after ECT than do patients without psychotic fea-
tures.16 It could be expected that more severely symptomatic pa-
tients receive a more intensive stimulus; however, we found that
the proportions of patients with psychotic features were evenly
distributed among the different pulse width groups. This suggests
that any indication bias due to symptom severity was limited.
The anesthetics used differed significantly between the dif-
ferent pulse widths. These differences may be explained by differ-
ent routines in the different hospitals. However, the choice of
anesthetics did not affect either remission or subjective memory
worsening at 6 months.
One of the inclusion criteria in this study was unilateral elec-
trode placement, with all other electrode placements being
excluded. Different electrode placements result in different remis-
sion rates and cognitive side effects.2,4,17 Considering that previ-
ous research indicates that electrode placement could affect
memory impairment, this restriction was used tominimize the var-
iation and potential risk for bias. However, our results may only be
generalized to the unilateral electrode placement technique.
Limitations
This study has some limitations. The first of these is the reli-
ance on subjective memory rather than objective impairment,
which was because of a lack of objective data in the register.
Therefore, it is unclear whether patients' experiences of memory
disturbance represent objective impairments or not. Second, the
restrictive inclusion criteria increased the statistical uncertainty
because they limited the size of the study population andmay have
affected the estimated rates of remission and subjective memory
disturbances. However, they are unlikely to have influenced the
relative effects between pulse widths or patient groups. Despite
being one of the largest studies to date on the long-term effects
of different pulse widths during ECT, this study was not large
enough to exclude clinically relevant differences in subjective
memory impairment between the pulse width groups. The study
population was limited to 312 patients, which is not large enough
to rule out the possibility of differences in the rate of subjective
memory impairment between the treatments with different pulse
widths. The point estimate of the odds of nonremission was 1.7
in the <0.5-millisecond pulse width group as compared with the
>0.5-millisecond pulse width group, but the difference was not
statistically significantly different. However, if this result was con-
firmed as statistically significant in a larger study population, it
would have been clinically relevant. A third limitation is that there
may have been an indication bias in respect to the choice of pulse
width for treatment initiation. Patients perceived to be at risk of
developing memory disturbances may have been treated with
shorter pulse widths to lower this risk; if so, this indication bias
might have attenuated any association between shorter pulse
width and lower risk of subjective memory disturbances. Further-
more, the current dosing strategy in Sweden is related to age and
sex but not titrated seizure threshold. Thus, it is unclear if the
results are generalizable to dosing strategies using seizure
threshold titration.
CONCLUSIONS
In this cohort of patients treated with unilateral electrode
placement, no support was found for the previous research finding
of a lower rate of subjective 6-month memory disturbances with
UBP ECT compared with BP ECT, but older age was associated
with a higher remission rate 6 months after ECT. Large random-
ized studies are required to exclude the possibility of long-term
differential effects between pulse widths.
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